Case Report

Disseminated Kaposi’s Sarcoma

Khadijeh Makhdoomi MD1, Azam Mivefroshan MD2, Mohammad Hossein Rahimirad MD3, Masome Rabeipoor MD2, Fariba Abbasi MD2, Afshin Mohammadi MD4, Ali Eischei Oskuei MD5

Abstract

Kaposi’s Sarcomas (KS) have been associated with many conditions and also known as a typical complication of immunosuppression. It should be considered as an important differential diagnosis in skin lesions of patients after solid organ transplantation. This is a report of a 61-year-old man, who presented with disseminated KS and a history of renal transplantation. We suggest systemic evaluation and visceral assessment in patients with Cutaneous KS.

Keywords: Immunosuppression, kaposi’s sarcoma, kidney transplantation

Introduction

Kaposi’s sarcoma (KS) is a low-grade vascular tumor that derived from lymphatic endothelial cells infected with type 8 of human herpes virus (HHV8) also known as KS-associated herpetic virus (KSHV). Iatrogenic form of KS is most often detected in patients after kidney transplantation which reflects the higher frequency in this population. KS is most notable for its cutaneous involvement, characterized by dermal purplish, reddish blue, or dark black macules, plaques, and nodules. Lymph node enlargement and visceral localization are other clinical manifestation of KS. Visceral involvement occurs in 25 to 30 percent of patients with kidney transplants and in 50 percent of those with liver or heart transplants. We present a 61-year-old man with multiple cutaneous lesions and disseminated visceral involvement in the stomach, transverse colon, liver, mediastinal lymph nodes and lungs 10 months after renal transplantation.

Case Report

A 61-year-old man with end-stage renal disease due to hypertension, one year after hemodialysis received a renal transplant from a living unrelated donor. His initial induction of immunosuppressive therapy was cyclosporine (6 mg/kg), mycophenolate mofetil (2 g/day) and prednisolone 1 mg/kg after three pulses of 1000 mg methylprednisolone daily. He had no episode of acute rejection or rejection-like episodes, broncoscopy was performed and revealed diffuse airway edema with multiple sub-mucosal hemorrhagic lesions in both lungs (Figure 4). Microscopic evaluation of skin biopsies revealed an area of hemorrhage and vascular proliferation as well as a collection of spindle shaped cells with positive CD31 and CD3 in immunohistochemistry staining (Figure 5). Overall, these findings were diagnostic of Kaposi’s sarcoma. Upper and lower gastrointestinal endoscopy was performed to diagnose the other sit of KS. The result showed blue plaques on esophagus and multiple ulcerative and hemorrhagic lesion on fundus and body of the stomach and also in the transverse colon. Unfortunately, we have not any possibility for detection of human herpes virus 8 (HHV8) in our center.

Immunosuppressive therapy was changed from cyclosporine and mycophenolate mofetil to Sirolimus. Due to worsening dyspnea, broncoscopy was performed and revealed diffuse airway edema with multiple sub-mucosal hemorrhagic lesions in both lungs (Figure 4). Microscopic evaluation of skin biopsies revealed an area of hemorrhage and vascular proliferation as well as a collection of spindle shaped cells with positive CD31 and CD3 in immunohistochemistry staining (Figure 5). Overall, these findings were diagnostic of Kaposi’s sarcoma. Upper and lower gastrointestinal endoscopy was performed to diagnose the other sit of KS. The result showed blue plaques on esophagus and multiple ulcerative and hemorrhagic lesion on fundus and body of the stomach and also in the transverse colon. Unfortunately, we have not any possibility for detection of human herpes virus 8 (HHV8) in our center.

Immunosuppressive therapy was changed from cyclosporine and mycophenolate mofetil to Sirolimus. Due to worsening dyspnea and disseminates involvement, chemotherapy with Bleomycin (15 mg Q 15d), Vinblastin (10 mg Q 15d), and Adriamycin (50 mg Q 28d) for six months was scheduled.

Discussion

KS is a rare cancer in the general population, whereas its prevalence is more common among immunocompromised patients including AIDS and solid organ recipients. Intensive Immunosuppressive therapy is significantly associated with higher risk of developing KS after transplantation. The rate of post-transplan-
Figure 1. A) Chest X ray; B) Chest CT-scan

Figure 2. Lymph node in anterior and middle mediastin (arrows)

Figure 3. Abdominal CT scan: Multiple round, hypodense opacities in liver

Figure 4. Endobronchial lesion (arrows)
tation KS was estimated at about 0.5% (range 0.06% to 4.1%).

Larger studies have described Kaposi’s sarcomas following renal transplantation. Usually, Kaposi’s sarcomas was localized in the skin, but visceral involvement such as lymph node, uterine cervix, gum, tonsils, lung and heart were also demonstrated. Because of the low immunosuppression in renal transplant, visceral involvement are expected in low frequent. In their case report, Ghorbani, et al. reported a 38-year-old man with isolated pulmonary Kaposi’s sarcoma 6 months after renal transplant. He died due to intra-alveolar hemorrhage.

It is important to note that 90% of kidney transplants with KS have skin and/or mucosal lesions. Primary visceral involvement and their clinical manifestations are unusual, extremely rare, and occur in 10% of recipients. Reduction or withdrawal of immunosuppressive therapy caused complete remission of KS in most patients. The conversion of calcineurin inhibitors such as Cyclosporine or Tacrolimus to Sirolimus (because of antiproliferative properties) is the most effective treatment. For patients who do not respond, the choice of therapy with a second-line agent (vinblastin alone or in combination with bleomycin, paclitaxel, oral etoposide, and gemcitabine) must be individualized, and patients ages and co-morbidity must be taken into account. In this case we described an unusually aggressive and extensive KS with pulmonary, gastrointestinal and liver involvement. According to our knowledge, the report of disseminated KS is common in AIDS, but it is rare after solid organ transplant.

In conclusion, kaposi’s sarcoma should be considered as an important differential diagnosis in skin lesion of patients after solid organ transplantation. Although skin lesions are the most common manifestation of KS but related to serious prognosis of visceral KS, we suggest systemic evaluation and visceral assessment in all patients with Cutaneous KS before any presentation. Systemic chemotherapy after immunosuppressive reduction or its withdrawal may be necessary.

References